Chemotherapy and targeted therapy in liver metastasis from gastric cancer.
- Author:
Dan SU
1
;
Li BAI
Author Information
1. Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China. baili0795@163.com.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal, Humanized;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Camptothecin;
analogs & derivatives;
Hepatectomy;
Humans;
Liver Neoplasms;
drug therapy;
secondary;
Molecular Targeted Therapy;
Stomach Neoplasms;
drug therapy;
pathology;
Taxoids;
Trastuzumab
- From:
Chinese Journal of Gastrointestinal Surgery
2014;17(2):112-116
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer remains one of the most common malignancies and leading causes of cancer death in China with a complex biological behavior. The incidence of liver metastasis from gastric cancer is particularly high. The indication of hepatectomy is controversial, however, surgery should be considered. How to choose the right regimen to obtain macroscopically complete resections represents a controversial subject. Newer generation cytotoxic agents such as docetaxel, S-1 and irinotecan as well as targeted therapy agent trastuzumab exhibit promising activity in gastric cancer. Further study and clinical trials are needed to confirm the benefits of systemic treatment in gastric cancer patients with liver metastasis.
